BVS
Bioventus Inc.
BVS has the edge over NVO overall, supported by stronger fundamentals and stronger valuation.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
BVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
BVS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BVS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $10.86 | — |
| Current | 14x | $10.86 | — |
| Cheap | 18x | $14.37 | +32% |
| Fair | 26x | $21.13 | +95% |
| Expensive | 69x | $54.91 | +406% |
Historical ranges are pointers, not guarantees.
BVS has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
BVS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
BVS has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
BVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.81 | +1.6% |
| Q3 2026 | $0.80 | +627% |
| Q2 2026 | $0.77 | +$0.78 |
| Q1 2026 | $0.41 | +$0.90 |
| Q4 2025 | $0.33 | +$0.85 |
| Q3 2025 | $0.11 | +$0.69 |
| Q2 2025 | -$0.01 | +$0.62 |
| Q1 2025 | -$0.49 | -$0.17 |
| Q4 2024 | -$0.52 | +$1.97 |
BVS's earnings per share have jumped to their highest in five years: $0.80 over the past year, up from $0.11 the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over BVS on earnings, with more consistent year-over-year improvement.
BVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $142.4M | +2.7% |
| Q2 2026 | $153.2M | +3.8% |
| Q1 2026 | $132.1M | +6.6% |
| Q4 2025 | $157.9M | +2.8% |
| Q3 2025 | $138.7M | -0.2% |
| Q2 2025 | $147.7M | -2.4% |
| Q1 2025 | $123.9M | -4.3% |
| Q4 2024 | $153.6M | +13% |
BVS's revenue grew through 2024 and has held roughly level since: $142M last quarter, up 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.8% | -1.3 points |
| Q2 2026 | 12% | 0 points |
| Q1 2026 | 6.4% | +2.4 points |
| Q4 2025 | 12% | +7.1 points |
| Q3 2025 | 8.1% | +5.2 points |
| Q2 2025 | 12% | +32 points |
| Q1 2025 | 3.9% | -0.2 points |
| Q4 2024 | 5.2% | +4.3 points |
BVS's operating margin was 6.8% last quarter, down 1.3 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over BVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over BVS on profitability, with a higher operating margin.
BVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20.3M | -31% |
| Q2 2026 | $18.9M | -25% |
| Q1 2026 | $8.4M | +$28.5M |
| Q4 2025 | $37.4M | +99% |
| Q3 2025 | $29.6M | +189% |
| Q2 2025 | $25.3M | +67% |
| Q1 2025 | -$20.2M | -$13.9M |
| Q4 2024 | $18.7M | +87% |
BVS generated $85M in free cash flow over the past year, up 59% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
BVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +1.7M shares |
| 1 year | +5.3% | +3.7M shares |
| 3 years | +15% | +9.7M shares |
| 5 years | +73% | +30.7M shares |
| Available history | +30% | +16.9M shares |
BVS has 72M diluted shares, up 5.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over BVS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
BVS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 3.0x | Elevated |
| Q3 2025 | 4.0x | High |
| Q2 2025 | 4.9x | High |
| Q1 2025 | 20.2x | High |
| Q4 2024 | 18.0x | High |
BVS's net debt is about 2.4 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over BVS on leverage, with a lower net debt burden relative to earnings.
BVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 19.8 | Oversold |
BVS's weekly RSI is 44 (neutral) and its Stochastic is 20 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
BVS PE vs Healthcare Sector
| Metric | BVS | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 48% below |
| PE % | 2 | 35 | 33 pts below |
BVS is trading at 14x earnings, a 48% discount to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over BVS on valuation relative to its sector.
BVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.9 | 16% below |
| 20 week MA | $13.0 | 16% below |
| 50 week MA | $10.4 | 4.4% above |
| 100 week MA | $9.16 | 19% above |
| 200 week MA | $7.20 | 51% above |
BVS has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
BVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.2 | $14.0 | -19% |
| 2022 | $14.0 | $2.54 | -82% |
| 2023 | $2.54 | $5.27 | +107% |
| 2024 | $5.27 | $10.6 | +102% |
| 2025 | $10.6 | $7.46 | -30% |
| 2026 YTD | $7.46 | $10.9 | +46% |
BVS has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.